期刊
ACS CHEMICAL NEUROSCIENCE
卷 5, 期 8, 页码 674-682出版社
AMER CHEMICAL SOC
DOI: 10.1021/cn5000716
关键词
Adenosine receptor; antagonist; GPCR; Parkinson's disease; lead optimization
资金
- National Natural Science Foundation of China [81273372, 81130023, 31373382]
- National Basic Research Plan (973) of the Ministry of Science and Technology of China [2011CB5C4403]
- China Postdoctoral Science Foundation [2013M541729]
- PAPD - Priority Academic Program Development of Jiangsu Higher Education Institutions
- [BM2013003]
Parkinson's disease is a neurodegenerative disease characterized by the motor symptoms of bradykinesia, tremor, and rigidity. Current therapies are based mainly on dopaminergic replacement strategies by administration of either dopamine agonists or dopamine precursor levodopa (L-Dopa). These treatments provide symptomatic relief without slowing or stopping the disease progression, and long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinisia. Unfortunately, there had been few novel treatments developed in the past decades. Among nondopaminergic strategies for the treatment of Parkinson's disease, antagonism of the adenosine A(2A) receptor has emerged to show great potential. Here we report the optimization of a new chemical scaffold, which achieved exceptional receptor binding affinity and ligand efficiency against adenosine A(2A) receptor. The leading compounds demonstrated excellent efficacy in the haloperidol induced catalepsy model for Parkinson's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据